Alkem Laboratories Concludes US FDA Inspection at Mandva API Facility with Zero Form 483 Observations
Alkem Laboratories Ltd 路 Press Release 路 30 Oct 2026, 8:52 pm
Alkem Laboratories Concludes US FDA Inspection at Mandva API Facility with Zero Form 483 Observations Alkem Laboratories announced that the US FDA successfully concluded an inspection at its API manufacturing facility located in Mandva. The regulatory audit was conducted from 26th Oct'26 to 30th Oct'26 and concluded with zero Form 483 observations, confirming strong compliance standards and mitigating regulatory overhang for the site.
Original exchange filing (PDF)
More announcements from Alkem Laboratories Ltd
- With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q2 and H1FY27 Earnings Conference Call'' .... 路 13 Nov 2026
- We wish to inform you that the Company has appointed Mr. Gopal Kothari as the CFO and KMP of the Company wef 2nd Dec, 2026. 路 12 Nov 2026
- Pl find enclosed press release and analyst presentation on Q2 and H1FY27 earnings and business updates of the Company 路 12 Nov 2026
- Pl find enclosed unaudited financial results along with Limited Review Report of the Company for quarter and half year ended 30th Sept, 2026. 路 12 Nov 2026
- Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 12 Nov 2026
- Please find enclosed herewith the outcome of Board meeting dated 12th Nov, 2026. The meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 13.40. 路 12 Nov 2026
- Please find attached herewith intimation of incorporation of subsidiary in the form of Joint Venture. 路 09 Nov 2026
- With reference to your email regarding the captioned corporate announcement submitted by the Company on 03rd November, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure .... 路 05 Nov 2026
